EMA Authorised: Degevma (denosumab) — Teva GmbH

View source ↗

Summary

EMA authorised Degevma (denosumab) by Teva GmbH for Giant Cell Tumor of Bone, expanding treatment options for this rare bone neoplasm.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Degevma (denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Teva GmbH. Decision date: 17/11/2025